Background
Hydrocortisone is currently the first-line treatment for glucocorticoid replacement in patients with adrenal insufficiency 1 . The treatment regimes have been designed to mimic the physiological diurnal variation of endogenous cortisol in a healthy individual, peaking in the morning with two additional peaks corresponding with meal times (Figure 1 ). This requires hydrocortisone to be taken three time daily.
Methods

Conclusion
Case study
Mrs. M is a 66 year old female who has had adrenal insufficiency for many years. This was diagnosed after Synacthen tests revealed complete adrenal suppression due to high-dose prednisolone treatment for pulmonary eosinophilia. She has since been on a 10mg-5mg-5mg hydrocortisone regime, with occasional recurrences of eosinophilia treated by restarting high-dose prednisolone. The graph illustrates the geometric mean (±2SD) of 33 healthy individuals at various times, representing the mean physiological circadian cortisol profile. The nadir is the trough cortisol concentration, while the acrophase is the peak cortisol concentration. Mrs. M has recently developed osteoporosis. Concerned about her condition, she was interested to find out which treatment had a greater deleterious effect on bone turnover. She experienced no difference in symptoms of withdrawal between the two treatments.
Conjugated osteocalcin (Gla-OC) is an osteoblast-specific product, and is therefore considered to be a marker of bone formation. We decided to measure Mrs. M's Gla-OC levels on two separate days, whilst she was on 20mg of hydrocortisone and 3mg of prednisolone respectively. Prednisolone has a double bond between carbon 1 and carbon 2 in ring A, while hydrocortisone has a single bond. The structural difference accounts for the variation in potency between the two molecules.
Prednisolone is an alternative treatment in adrenal insufficiency 1 . It is structurally analogous to hydrocortisone, with the exception of a double bond between the first and second carbon atoms in ring A of the molecule 3 (Figure 2 ). This structural difference confers a longer half-life and higher potency 4 . Thus, prednisolone can be taken once daily. The bioequivalence ratio between hydrocortisone and prednisolone is commonly quoted to be 4:1 1 , reflected by the clinically prescribed doses of 20mg (10mg-5mg-5mg) of hydrocortisone and 5mg of prednisolone. However, the clinical application of prednisolone has been limited due to reports that it has greater deleterious effects on bone turnover compared to hydrocortisone 4,5 .
Recent evidence from Caldeto et al. suggests that the bioequivalence ratio between hydrocortisone and prednisolone is 6-8:1 6 , instead of 4:1. Using this ratio, 5mg of prednisolone would equate to a higher dose of glucocorticoids compared to 20mg of hydrocortisone. This offers a potential explanation as to why studies have found that prednisolone has more adverse effects on bone compared to other glucocorticoids, as an over-replacement of glucocorticoids has been demonstrated to be associated with osteoporosis 7 .
Therefore, more research has to be conducted to compare the effects of lower, more physiological doses of prednisolone with hydrocortisone on bone turnover.
Samples were acquired when Mrs. M was taking 10mg-5mg-5mg of hydrocortisone. After which, she suspended hydrocortisone and began treatment with 3mg of prednisolone. Samples were then collected after 2 weeks of consistent prednisolone treatment for comparison.
To account for the diurnal variation of Gla-OC, concentrations were measured 2, 4, 6 and 8 hours after the morning dose of hydrocortisone and prednisolone. Gla-OC concentrations were also measured 9 and 10 hours after the morning dose of hydrocortisone.
Levels of Gla-OC were quantified using commercially available assays (TaKara Osteocalcin (Gla-OC) EIA kit, TaKara Bio Europe/Clontech, Saint-Germain-en-Laye, France).
Results
There was no significant difference between the mean Gla-OC concentration measured 2, 4, 6 and 8 hours after the morning dose of prednisolone (8.25ng/ml) and hydrocortisone (7.73ng/ml). Gla-OC was also measured 9 and 10 hours after the morning dose of hydrocortisone (Table 1) .
From these results, it appears that there is no significant difference between the effect of hydrocortisone and prednisolone on osteoblast production of Gla-OC. Mrs. M chose to remain on 3mg due to its convenient once daily dose.
This case study demonstrated that Gla-OC levels have the potential to be used to monitor bone formation in patients treated with glucocorticoids, guiding the choice of medication. Long-term follow-up of the patient's bone mineral density would be necessary to investigate the correlation between suppression of Gla-OC and osteoporosis.
